ELTP - Earnings call transcript Q3 2018 | Elite Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen. And welcome to the Elite Pharmaceuticals’ Conference Call. At this time, all lines have been placed on listen-only mode.

Before management begins speaking, the Company asked the following statement. This conference call contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this conference call. or by such Elite’s ingredients factors involve performance approval inability may ability transfers the that including, and of to materially be cautioned different such of limitation, the the results, of without not to ANDAs obtain are necessary forward-looking delays, risks statements forward-looking control may that Elite, uncertainties which these the approval Listeners process, timing to and uncertainties, the obtain actual of results, implied Elite other other or be expectations cause performance under of or statements. achievements FDA from of forward-looking at CRL, of action regarding FDA all, statements the of and the to require may by the if of NDA. SequestOx approval result approval, FDA, the the of take the These of may statements the steps obtain the expected in include order Elite Elite timing a as the all, and of the obtain may forward-looking timing in order of approval, statements the FDA the expected by to approval at regarding NDA. if the require SequestOx Elite These include FDA statements actions of guarantees future These are not of forward-looking action or statements performance. on discussed reports from by future are its filings These Elite’s sources, results in and without other and factors, Administration or property, ability other and Commission, and the timing including protections Elite’s the with XX-Q obtain Drug the Food and XX-K, approvals funding clinical and regulatory authorities trials, defenses, and Exchange intellectual Securities and Forms under and regulatory X-K. LPC of Agreement limitation, pending sufficient or the risks to including, other reviews future a whether alter or its result under statements, is Elite update otherwise. to of information, new or obligation as events no forward-looking host, over pleasure the floor now Mr. covered, to that to it is my With turn your and Pharmaceuticals. Chief Officer Nasrat Hakim, Elite of President Executive the is Sir, floor yours.

Nasrat Hakim

call. Nasrat you, Elite’s I am and Good is ladies is name Hakim. morning, and President Kate. CEO. Elite’s My This earnings gentlemen. Thank

update answer questions on our R&D Dianne. sales of which, pending facilities, come SequestOX summary floor. have an ANDA’s, Chief marketing you Elite’s submitted will FDA give pipeline Financial I’ll few So and back that Carter have After to financials. you with and Ward, Officer and the us Ward, high Mr. and

Carter Ward

Thank calling ended for XX, in filed for for quarter XX-Q the we December our the you, months and XXXX. thanks Nasrat, today. nine and everyone Friday,

We’re year. on a March fiscal

So get third the is site, quarter of section of ending on wherever the Investors Q fiscal XX, your December is our filings. XXXX. which year quarter SEC or you is the may Web else our elitepharma.com, March available

going those yet, haven’t seen I sites. get analysis financials your am take give parts some you please through questions and of numbers. those of context best some other questions do or I to copy as If and to and our the and one that you address Q on from briefly key of follow are our from elitepharma.com related. all of and from comments others Also, you that we comments my the received always, will shareholders financially Elite, and the

but year. compared quarter, to they lines; above a September quarter. $XXX,XXX for which the as year-on-year the that’s Lodrane, prior revenues it’s down around So start XXXX they Hydromorphone, the the to to were for December with increase all Isradipine, revenues slightly the and growth quarter first is or $X.X $X.X million significantly Naltrexone, last The the up XXXX quarter, were decent year’s million December as our were all for prior attributed were revenues compared compared across increase, Phentermine, of let’s XXXX almost Phendimetrazine, Methadone to prior the product year, P&L, so X%; XXXX December

that’s in time is to important on and And that’s you are comments One We're thing honoring is Methadone to probably them. received be will giving up to Nasrat to from been on product Methadone revenues all The we renewal. term quarter, about continues quarter. role growth and quarter most the from and revenues of So an of Last orders update insight more that I to a to manufacture going September is on part the something year quarter a a XX% few in quarter-to-quarter basis quarter. XXst. long give are of decreasing December just prior all did near is in very due play a contract on you have will we they Isradipine, million. up contract we those term, Last and that Phendimetrazine, I Methadone like Elite, compared getting that mentioned product an that contract a that growth be and in also they lines reported both that customer technically year-to-year manufacturing to to purchase that's up customer to a we again Methadone, Methadone next plans. our been the the large into product we compared the last We've on this this increase, for contract all last Phentermine, for we our Friday, that aware manufacture once orders to leaves part million with quarter-to-quarter line; on about here and increase from and a takeaway throughout strategic demand talked last development that on had $X.X increase expired revenues me that. compared to quarter us. were Hydromorphone, product the in spoke were but the get this for product. and There still on this and customer XXXX discussing the that revenues Lodrane, December of Elite's be we working were the our $X.X Naltrexone, the quarter, basis would basis. continue up which But see. manufacturing’s observation a in for

to continue time. expect to Methadone some do for and make We ship we and so

the for million to were as $X increase million increase. quarter this million expenses, XX% Moving to which approximately quarter, down $X.X to $X.X P&L to XXXX December R&D compared the

quarter expenses. the comments to SequestOx. In reformulation and R&D and development this previously study to which The Where point of important pilot important, being ANDA conducted request what the successful filing And the the was achieved. response Elite in every SunGen, pipeline multiple how spent the and ANDAs that the costs I Now numbers of these at quarter, R&D to to development that on led remains case. was equally continued products incurred relating filed. with completion first in last product week, what diligent this were FDA were the incur and looking but out are is was done money and co-developed of

on know. that's Also like last something It’s call, have of potential of products, FDA, the filing of repeat just important our that study so the little demonstrated those NDA results are today, because far. in we are the or SequestOx, some actively remind developed now five where Elite's in been center costs persona. several ANDAs the an for our detail. other is incurred cost composition And and it I of product to to I'd outstanding and results for Just pipeline. with That's and being development importance which a pilot pending to you investors have current our discussed more a an in has capabilities which part the

upon doing, costs raw So clinical materials, costs R&D we're paid and consists external parties. internal. will other Depending third trials, are either various regulatory to what vary. costs or costs of these fees External

I of knowing Some lab of an people cost quarters I where insight the have resources costs materials the what stress purchase mentioned into expensive employees, importance in may that just particularly gives expense the development was is This Elite running is joined XXXX. to clinical area as be in done Internal or seen higher not and I've we remains mix are a our is incurred. I proper our some being and It as amount Elite's trial and capabilities. key. our actual is costs. resulting product portion activity the factory. high Having and internal of But since an

more and chemist affairs have regulatory in past. technicians personnel formulators, than We the

resources resources us with our upgraded are quantity product development And to and important few product in to as Elite. factory between resources understand most shift that's quickly And improved have regards and are Our realize the commercial and size, with facilities with past development over able and those people, our We're significantly of to and needed. to due equipment. importantly, years, been manufacturing we labs that most nimble current providing quality. both with

as we nevertheless resources are what's regards our it with critical But and by to the which and number, is successful to lead. R&D sometimes on that takeaway know is so is is you right impairment, the much as not but is doing people, So just it's to know facilities, The to and achieving to there Ks more so particular want filed. Qs spending much that demonstrated understand important filings if by spent. there being that are trials, what

on the P&L Finally it’s little in loss statement, and compared relationship at into less this to as $X.X December commercial compared we R&D the operations. XXX% quarter a last loss P&L reported to the what not loss this insight correlating so million operating spent quarter on than the approximately and important $XXX,XXX gives this good was between The R&D, of out. XX% one $X.X really $X.X Once jumps quarter, costs while of level loss million million completely more XXXX to an we Elite’s or operating higher year. again, for closely look

are and on So we the less operations, remember ops what we overall The the in by to us that our that our revenues than contributing P&L to need part they operations. demonstrate profits and our doing loss to just commercial generated R&D, commercial important spent R&D. are the fund to is operations, commercial

if moving go the So R&D that positive, the is they losses these losses, are through commercial types indefinitely, achieving clearly, operations filings are on of even our FDA but can’t process. overall

moving development achieving the are are forward and a we trial with positive We pipeline. diverse results of

there the the queue through we’re one takes that moving our in in value. to this before last pipeline that’s of increase is was the received I toward over, approval summarize, Our Item factor currently everyone Congress. that this signed optimism on areas the of and disclosure mainly new and is were to a December towards like thing the to on law this business realize pipeline of just Elite, us commercialization of XA else on helping future There not operations the queue. the and new section our is in of that’s get question The my is And profits commercial two effects industry, level and current working tax the pipeline both a they’re us. in affecting tax in effects us of future, But risk our the and are one there and this shareholder towards pipeline indicators commercialization that of profits. we’re model support Nasrat

First, change the operating a losses there losses two which will effect on it’s the reported we are we income in when offset have decrease deducted. taxes. and profits losses net past, future operating of in This profits. earliest and is us accumulated achieve how used therefore they’re and to future the are Net factors taxable

operating to valuable which income. large to XX% loss, the operating that all Starting are says is up law, of new fully We net against tax NOLs, losses, to only these a operating this a new deductable prior are Elite. the net to losses profits. have year, net the law Prior item deductible future XXXX,

Now whatever a just that they’re the to but carried use forward not NOLs year, you loss year. they’re in in next fact can’t amount the of particular

of able to rules one them, prior longer. they’re the follow the be old So them on important deduct still they to all that grandfathered it’ll that just it’s thing you’re in. little And to takes accumulated eventually NOLs XXXX, going more a still

year that So it’s just the this effective. from on are fresh NOLs

make minimal. change in later become net that it that have So would and I’m then an on effect sooner effect loss the and rather the operating hoping does profitable Elite rules, we’ve than this

the need effect. big withholdings on tax new rate once decrease in have One that tax on we in I’ve profitable payroll law the and company’s a the XX% the from that’s other be to thing, the paychecks. decrease again, process is But obviously also noticed and XX% significant to tax I first. deal Second a everyone’s would it

our by they’re I'm which paycheck, getting So affect, employees, includes employees Elite that me, appreciated doesn’t and an has all that employee. a but also it’s bigger our a corporation,

would give Chief like Nasrat update our his Mr. an Hakim Executive comments. and Chairman Now, and to Officer,

Nasrat Hakim

one via did not questions talking about Dianne paycheck, you’re I that Carter. email phone in you you, increase my received given Thank and me on since years. notice calls. X.X haven’t several

we So have second I first, my tried around; that like to you would what received. organize to presentation I questions on the update and

status FDA, and sales So R&D covering and GMP we'll updates, and facility the of SequestOx projects pending be ANDAs, pending marketing.

ongoing pipeline on with the and strategies. Elite’s progress I'll our a So and start of activities review

our we'll on NDAs So recently that and with start for our is news We reported pipeline, good SeaquestOx. very SeaquestOx.

review of product. let So with me this a start

that new we from the the into all You the and we the brand, the That lab had simulating over the modified certain importance formulations our with solution the showed delay was issue promise in that study we recall, the to remember our Tmax we modifications might how last we was Tmax of SeaquestOx these and from shorter in issue of had translate original I Lab the only in FDA hoping studies were address if formulations thought the showed formulation. conditions, investor will with you a about had only SeaquestOx modifications vitro. Tmax. might solution have And -- in that some improved improved the passed fat call identified Tmax. versus discussed substantially Medias updates attributes that

end, to down, humans, study only order a humans modifications work So large ran and a us to pilot This decided work a pilot if keep still allow in go study. we cost. we one would to study out in pilot that XX cost study the more would the out on rather will with pivotal modifications found We the was on if contain than order with find than formulation bioequivalence also a to it subjects. the on and

forward subjects. XX results, modified outstanding. best with area improved time original is the of pilot The study Tmax X.X drastically were XXX% between a results dose formulations the the drug, we for the path a and to a original presentation The the FDA. of bloodstream. option hours drug. is partial Tmax Tmax drug. SeaquestOx into was hours AUC, a study the the hours and Our X.X reference a formulation. take measured will into for The mean have partial both where believe to AUC for was SeaquestOx In with under of over the different drug, hours therefore subjects formulation the the Roxycodone. be was that for of step curve to to was to SeaquestOx. XX% amount The compare study. goal XX hours modified products. with This pilot Based that reference of the forward hours to drug also The it improvement dosed pilot, identify AUC essentially and single the X.X range the a points. for was XX% We the The number XX%. The on were formulation bioequivalence we drug results next with onset identical. gets the this for larger modified This we SeaquestOx formulation measure for randomized that X was reference was the The a X modified was the pilot and to reference X.X the equivalent range to of dramatic the subjects performance

the modifications confirm to modified will need previous will FDA SeaquestOx this apply formulation guidance We on their that formulation. to SeaquestOx

are what resubmission confirm can the of we for NDA. studies So needed

would formulation to people final SeaquestOx. report commenting will until FDA inspection at of completed Some technologies, I toward technology. inspection. XX for about facility in time. New study we we an tested release. filing it with about because positive continues not Indeed, NDA continues product the unless granted facility range commented has of recently be Jersey. our PDUFA I extension that XXXX points also it and press to of listed that But Elite product fee extremely FDA pilot or about are Elite early at am the we further as end this. a abuse-deterrent this development, excited sequest month goes naltrexone is not the at time. space FDA that me and was formulation used that in you one The happy and very the on and before a we in the the resubmission showed until This SequestOx abuse-deterrent waiver mention the that in the

First, we Action for Elite. potential by you December in no inspection have inspection observations. preapproval have that same Indicated, filed previous issued about we shared inspection conclusion time that letter. classified the out for warning of us we applied the an we ANDA the NAI. This regarding before a letter from letter December, the restrictions was in December, as The in might warning pharmacovigilance the with FDA FDA At At any receive that removed the year. close No an that got

of the last they am received FDA a was inspection Indicated. the four observations Action pleased positive strong in whereby facility. our zero and compliance observations and of for inspections build Like inspection a with and classified our very just company for addition, products small company. again covered week, to systems. No GMP and quality launch improve nevertheless outcome proud as December, foundation one new was company another systems. this from of quality This these to also completed inspections. continues full no worked In is inspection This I Two we hard pipeline. outstanding which our Elite a any the on and provides

Elite release partner commercial immediate strength we’re in SunGen. ANDAs was SequestOx, has our review for pipeline. company. this and substantial and product has of soul most co-developed filing week it with The pipeline the company CNS value. products clinical ANDA Nervous was known already System, new many what heart that with and that on pipeline, an Central recent our and FDA an we ANDA have last currently in development products of five continues Elite studies, To is all its our represent best Our two development but but We for, NDA our is in focus the perhaps may

For sales sales submitted million. there is which generic and are SunGen. which brand of to $XXX expected a there that generic And are submitted extended It billion. filing quarter. be next release Next next, co-developed for brand approximately is of product and ANDA This generic to with also be expected is was an X.X we

studies successfully stability of and have Sprinkled we required. most We bioequivalence have completed the Fed Fasted, require all the completed and

file one filings. respond to Elite next including of continue ANDAs, requested week We expect filed is each information going which by new to be quarter. to avatar this has FDA and the these five filed just for our to we we last product,

quality our the continue pipeline, and a and filings soon. Elite's company experience, build for responses, we source We we the filing Growth and growth the our stock. is pipeline to improve in regulatory of for As future for forward our stronger filings. those gain look products approvals for we to this our of group

stock. We heavily To launches, our summarize, begin in a large a number is products and company size. And for our we we approvals This have NDAs pending. see these as five into have on substantial we to our receive to growth pipeline. invested expect company the

We provided and size. our see will that substantial the you pipeline market are have these in markets of in products revenues products for

to We product formulation file cases forward Naltrexone this products the oxy layer. we very to study. see A of Tmax pilot in news excipient, first excipient believe I path naltrexone outside as SequestOx was was the address Naltrexone both to FDA. these and a approvals I us B. for were modification the the only the FDA with There to expect study, pilot by We the about We used modification ran no was was this in creates said asked with as the for layer. modified it concerns if able one B. part minor expressed on soon. and In to the was positive. The and a

no we'll till we back hear However, so FDA we wait first from surprises. will have

product activities. We Elite submitting continue other to on future to this be spend development products expects year.

filing and be lead end we As could generic that clinical extended I be potentially filed be will will with the trials mentioned, towards SunGen the this of year. co-developed quarter. are products There for conducting next other

consistent. financials Finally, have been our

products on about million as substantially provide which based revenues grow Our base, a our quarter pipeline are $X can launched. per we

believe continue and to the get of reflect Elite's price to as believe Elite value underway expect does grow positively price and We launch. the that price developments the current is products the We to approved pipeline not on we we the undervalued. react

so One of about marketing. sales sales say quotes and questions marketing, couple and the about I'll was of

options. by As all that group its I've disadvantages; sales advantages advantages get before, to updated has multiple disadvantages can We and start and that keep marketing the you we ourselves got it, and to remanufacture you profits; have Anytime the issue you the to costs you and or is you that don't all several lots, with get need capital. months. you for working the paid sell create carry there the

dollars company stopped. carry dead-weight So for for and small of that millions you that a of us have while is that to like

partners We our launch are about spoken and partners. We speaking sales marketing. and with of can have several also current one to

We TAGI. would Dr. that Epic Reddy, have solve the issue. working and three, And capital

set sales All marketing for can and two both products SunGen with are so share to with SunGen incoming have common us our have venture, ideas the Elite's up And these the make joint to team tag you'll However, spoken for would between on and SunGen. sense products that because the we entities. are about It in we entities. products have with many sale profits not finally, possible. we products along to a

I earlier, decide, not Several whatever I'll so we with have But be questions try decisions were submitted made as best as We interest. yet. many as we'll over in and any can. go Elite’s definitely stated I

statement Purdue The made. first was a regarding that

to weekend an the what doing. law it law about my a arm. is I articles that opioid by to have few no with the IP you read that heard of Purdue always insight weekend In I’ve the Purdue that other longer pharma a opinion, municipal the has state [indiscernible] series the is own Television this epidemic. I news and I as subject. this the promoting lawsuits Purdue oxycontin to opinion think news In Purdue it impact or and firm that on of doctors. was company for is comment positive/negative an opioids blame the can contributing Pharma I and it thought

in their interest. anything not So they that do best is

Now to that doctors. fact of the only the medical have marketing they not sales community they’re not The cut XX%, catering in who force oxycontin. by and is heard

So every anybody I of sued to was they’re this or I single us benefiting from getting because not to action with and just because going they product up state. sure symbolic benefiting except am to a allow the do that by get see gave our anything not that that gesture, about doctors them. doesn’t market compete not

Oxy long to December, turned lawsuits in As of The stop from supposed others go six Status entering in their filed. in communicate and than Status the the weeks and other APAP, SunGen The the they anything amendment the FDA as and market, and soon delayed. to the their over be week. trouble in with July as is they’ll continue decision applications they to with as supposed filing review that for responded symbolic application. multiple We it got add-on application us We went they’re the the October. filing partners, thing doing the was to actually they’re finished, to because it. and And SunGen. to of we was name last that took they partnership file states. between

with SunGen in shortly. amendment that. Status this will two than project anything we that communication We to filings, beyond addition later. go sooner we to filed and have Hydro We I the product out have the of manager yet. responded am with other not APAP, ensure not constant in heard that the for prioritized is

that. on behind running We’re

Nasrat Hakim

response Honestly, thing before file the drugs the simple, the filed, are ANDA and and or later, different. your Do something it you long launch with and through you can they and -- the the don’t go where once ahead give go queue? FDA? how change something from we labeling FDA, After prepare response, I is you the each a ANDA expect the amendments in And are indicating complicated. know complete approval entire want more

them tablets when are you not details, I’m half. go filed take Both going is half Hydro is have test tablet to you one example. through tablet APAP. APAP are break on a and Oxy scored, saying it all of regulations means that you when So There and scored, give I’ll We in scored. it but the you’re can a what

So then we the reviewed put half, Oxy everything for FDA which compare we on in and was made fine. them brand chamber tablets, them it. an APAP, that half them back cut tested The first call for them plus the we scored it. XX have file did issue stability and to ask Hydro for and chemist days could no what for we with decided more exact Oxy. when break review APAP, result kind to same and they filed know thing you We the impurities one of This wanted thing, did us

So drawing back put to we test report samples stability, have put FDA. them board, back to them the and to the make them again

is to an to where that the keep the queue. have in more the obligation So beefing asking. the answer that up question dictates is its time, be that the with we’re with you this questions. but to FDA comes up it keep yes, and questions the take And doesn’t registration department with answer FDA extra to Their up how minus long sit does why the

things of are some consistent some not. And and very are

we facility zero than as it be to more I said, that. passed So letter the response [indiscernible], for doesn’t us. creates The the I for have done? issue Hydro, Has that. been response an facility, it’s for FDA and two holding filed work such Is get better complete back-to-back just on inspections for or as back Elite’s there needed approvals answered the with anything

it’s tell can’t hopefully I'm a approved time. I of Does the applications, confident questions few within holding the I'm months. feel up and the up FDA holding will it all will review ask Yes, But the to approved? matter Nasrat confident just it's two you when, not be the anything. it’s this definitely these time is not So will hoping What’s FDA that responses. it be our takes very soon. next

we the Okay. The then sent see the I underscored hear inquiry does we’ll and we're and QX of ANDA? the it. or expect year response, they generic? on We’ve generic now perhaps provide process We about undisclosed from in really disclose to not to responding QX oxycontin but this When in do, corner. more as FDA FDA next much our all the Once status of Elite the am SequestOx? for on back them. an generic right following. in hoping -- of an to Nasrat approval Update to January study want except the they'll ball that, respond approve There can color is pilot the steps. the is then to

SequestOx on platform, with it is works and other extremely can one the for all Oxy once on but this not only results, opioids. it IR a use happy We are we anti-abuse, because

the So We very to ask ball doesn't make studies the sure more that. that hit with cannot Tmax like curve and another us with afford. FDA we that happy want we're for

of So determine and it to writing and their SequestOx, definitely our FDA questions soon are analysis submitting their hopefully The okay. up regarding response following by response, our SequestOx move. pilot are formulations will Naltrexone? we'll Did be with we sent next Question Dr. test versions W submitted without was Naltrexone. -- the Elite results, of SequestOx Both PR The them of two or questions. were for somewhat with confusing. successfully

difference. third The one had the technology

SequestOx have our exactly the since in used three, tested same its of all two trials Naltrexone we that inception. we were for B So

The without, repeat avoid no to don't FDA this. there bridge the to data exactly do Elite If the indicated anticipate change we trail? PX issue. Okay. to clinical That layer. have to Does was it last excipient why was to is original the to having and The this in SequestOx time HAL an that. allowed submission outer change not was Again, being with?

to DE that need and the Now more go because costs ANDA in you thing? refiling yes, then then and back if of successful, for like writing, are about the they it come I don't how upfront. all the I one would do with, want running it trials we through We

We are not Pfizer.

a are cannot to We lot money. afford that company a of waste

FDA, you from formulation when they extremely us, I So like study? Tmax say, number SequestOx end your the on file. and within When also a SequestOx’s We you get cost. to determine without happened the would to included question we to FDA? that to to will next to what formulations this Is is again the is Can on unique respond compiling tell to or deterrent the share am about to maybe about abuse there pilot IRs XXXX? immediately, of except apply The going in all to data because step excited that will depending the details time so. XX% that of I'll anticipate first data No, them platform hear the present it month Naltrexone exactly SequestOx, I the tell one exactly from filed started next and still you pilot it we're any of be by the was step. our

approval, So excited pattern we're extremely few Once little can trials, partnership, a still is we’ll update a Again, say launches and approval we non-concurrently next ADT, hate it. a I trademark. this, early this I FDA working let expect the it's Question about little guys we which more and out Dr. find the do question about know. we the once answer files best to get Smith this oxycontin, Norco, about too this, time. then months. Once we’ll realistically you but ANDA soon was How given? in at the more on we but Percocet, can't

SequestOx the trademark this, Smith? of a was stockholders there not that particular Some renewed. for reason Dr. Is noticed

Kenneth Smith

to law the trademark we're both and So is mark, to law. federal still common using but SequestOx mark subject

used federal follow if the but with filed it we registration, because to we commerce. mark, intend in it hasn’t use So been

once commerce product FDA the then the it’s used it, actually and So approves be in it in unless approves commerce. used can’t FDA

intend on says, is statement in marks only But XXXX. years have in And use we a that started these approved three you ours use to statement using a of particular to commerce use. actually file and December approved, this this statement of it So was are XX, date. on

unlikely still in do. commerce at So December trails XXXX Nasrat and said Simply things to will by about it we’ll that actually that time. the because be what XX, using need

to So mark date. at I’ll to some have refile this use intend later

press it’s trademark, said, a in it So all stuff. I has to we’re and we up like in commerce it releases used be just given on our and haven’t using

to it’s subject And so still law. common

have it up a of and keep file we’re we’ll right it’s use. statement before probably But able we’ll So it, with now. it to to still pending refile refile

Nasrat Hakim

And thanks… Dr. you, Thank Smith.

Carter Ward

subject our best. from He technical is we thing, IP in-house people who expert heard answer Smith. the the That’s questions guy that’s one his and best like Just you as get Smith Dr. Ken matter Dr. to haven’t knows attorney before. it’s tell, get could the

Nasrat Hakim

And Dr. Smith has a MBA and only. JB PHD in bio-chemistry in addition to

Carter Ward

Well, you thank wonderful that Have was gentlemen. a our last day. question. Thank And you ladies and operator.

Operator

today’s you, conference Thank and does call. ladies Yes. conclude This gentlemen.

a Thank for at participation. phone disconnect time your may day. wonderful this have you You and your lines

Elite Pharmaceuticals (ELTP) 12 Feb 182018 Q3 Earnings call transcript